# Trade Mark Journal No.2025/025 20 June 2025

## WO0000001857586 (1,5,40,42)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:7 April 2025
Date of designation in the UK: 7 April 2025

International priority date claimed: 26 February 2025 (European Union Intellectual Property Office (EUIPO)) (019148410)

Class 1
  Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes; cell cultures, cell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes; cell cultures, and cryopreserved cells iPS cells other than for medical or veterinary use; compositions and materials for scientific use, including cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, including genetically modified iPS or differentiated stem cells.
Class 5
  Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom, for medical or veterinary use; cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use; genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.
Class 40
  Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, including manufacturing in GMP-based facilities; custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, including manufacturing in GMP-based facilities; custom manufacture of cellular therapies, including manufacturing in GMP-based facilities; manufacturing of cell lines (modified cells with specific genetic edits) for use in generating other cells.
Class 42
  Research and testing of cell-based products, in particular therapeutic products; research, optimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom; scientific research, design and development of scientific cell culture, cell therapy or gene edited cell therapy; scientific research, design and development of cell culture, cell therapy or gene edited cell therapy, manufacturing systems and manufacturing processes for others; platform as a service [Paas] in the field of cell therapy, and cell therapy development; providing temporary use of a technological platform for the manufacturing of cell-based therapies, including technology, processes, and data analytics capabilities for process optimization and quality control.

Celyntra Therapeutics SA

Representative: NLO SHIELDMARK B.V., New Babylon City Offices. 2e étage Anna van, Buerenplein 21A, NL-2595 DA Den Haag, NETHERLANDS